Difference between revisions of "Lobaplatin (D-19466)"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "manufacturer. Instead" to "manufacturer. Instead") |
Warner-admin (talk | contribs) m (Text replacement - "Category:Drug index" to "Category:Drugs") |
||
| Line 12: | Line 12: | ||
<references /> | <references /> | ||
| − | [[Category: | + | [[Category:Drugs]] |
[[Category:Intravenous medications]] | [[Category:Intravenous medications]] | ||
[[Category:Platinum agents]] | [[Category:Platinum agents]] | ||
[[Category:Alkylating agents]] | [[Category:Alkylating agents]] | ||
[[Category:CFDA approved drugs]] | [[Category:CFDA approved drugs]] | ||
Revision as of 23:16, 13 June 2018
General information
Class/mechanism: Third-generation platinum compound with DNA alkylating activity, producing interstrand DNA crosslinks, which result in apoptosis.[1]
Route: IV
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.
Also known as
- Code name: D-19466